ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Actinium Ac 225-DOTA-Anti-STEAP2 Monoclonal Antibody AZD2284

Its studies are mostly in Prostatic Neoplasms, led by AstraZeneca.

Furthest: phase 1, since Mar 11, 20251 company-led study, 1 open or runningNext primary completion: Apr 16, 2029 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca11 open or runningphase 1since Mar 11, 2025Mar 11, 2025Apr 16, 2029phase 1 · NCT06879041
  • Named in AstraZeneca’s own pipeline as AZD2284, phase 1, as of Oct 30, 2026 (source).

Also a collaborator on its studies: Parexel.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 11, 2025First study: phase 1 study in Prostatic NeoplasmsFirst studyNCT06879041 · 136 planned · United States, Australia, South Africa

Ahead

  1. Apr 16, 2029Primary completion: phase 1 study in Prostatic NeoplasmsNCT06879041

TargetBeta

“A radioimmunoconjugate composed of a humanized, immunoglobulin G1 (IgG1) monoclonal antibody targeting the tumor-associated antigen (TAA) metalloreductase six-transmembrane epithelial antigen of prostate-2 (STEAP2; STAMP1) conjugated to the bifunctional, macrocyclic chelating agent tetra-azacyclo…”NCIt, read by Claude
“A radioimmunoconjugate composed of a humanized, immunoglobulin G1 (IgG1) monoclonal antibody targeting the tumor-associated antigen (TAA) metalloreductase six-transmembrane epithelial antigen of prostate-2 (STEAP2; STAMP1) ”NCIt, by rule

Other programs on STEAP2

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06879041Prostatic Neoplasms · United States, Australia, South Africa1RecruitingApr 16, 2029136

How it is read

Names in the registry

  • “AZD2284”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.